A Phase 2 trial just began testing whether a GLP-1 drug can slow brain shrinkage in progressive MS, and it could finally answer a question diabetes researchers have been circling for years

A Phase 2 trial just began testing whether a GLP-1 drug can slow brain shrinkage in progressive MS, and it could finally answer a question diabetes researchers have been circling for years

A clinical trial that just began dosing patients at Johns Hopkins is testing something the diabetes world has suspected for years: that the same class of drugs millions of people take to manage blood sugar may be quietly protecting the brain from shrinking. The trial, called TAG-MS, is tracking brain volume changes in adults with progressive multiple sclerosis. It is the most direct attempt yet to measure what longitudinal observational data has…